阅读说明：本技术 一种用于减轻原发性痛经的光疗装置 (Phototherapy device for relieving primary dysmenorrhea ) 是由 刘木清 林上飞 于 2021-08-03 设计创作，主要内容包括：本发明公开了一种用于减轻原发性痛经的光疗装置,包括壳体,壳体内设有光照模块以及与光照模块电连接的控制模块,壳体外侧设有用于控制光照模块的开关。光照模块包括多个LED发光芯片和用于固定LED发光芯片的固定板,LED发光芯片峰值波长范围为600-1000nm,LED发光芯片可产生脉冲光作用于子宫肌细胞形成光疗区域促进一氧化氮的合成、释放以及促进环磷酸腺苷的释放,增加血流量减轻痛经。控制模块与LED发光芯片电连接,控制模块可对LED发光芯片进行独立恒流驱动和PWM调光。与现有的技术相比,本发明具有如下优点：该用于减轻原发性痛经的光疗装置可有效减轻女性原发性痛经的疼痛强度,对人表皮皮肤没有创伤和不适感,没有使用副作用和依赖性。(The invention discloses a phototherapy device for relieving primary dysmenorrhea, which comprises a shell, wherein an illumination module and a control module electrically connected with the illumination module are arranged in the shell, and a switch for controlling the illumination module is arranged on the outer side of the shell. The illumination module comprises a plurality of LED light-emitting chips and a fixing plate for fixing the LED light-emitting chips, the peak wavelength range of the LED light-emitting chips is 600-1000nm, the LED light-emitting chips can generate pulsed light to act on uterine muscle cells to form a phototherapy area to promote synthesis and release of nitric oxide and release of cyclic adenosine monophosphate, increase blood flow and relieve dysmenorrhea. The control module is electrically connected with the LED light-emitting chip and can carry out independent constant current driving and PWM dimming on the LED light-emitting chip. Compared with the prior art, the invention has the following advantages: the phototherapy device for relieving primary dysmenorrhea can effectively relieve pain intensity of female primary dysmenorrhea, has no wound and discomfort on human epidermal skin, and has no side effect and dependence.)

1. A phototherapy device for alleviating primary dysmenorrhea comprising:

the illumination device comprises a shell, wherein an illumination module and a control module electrically connected with the illumination module are arranged in the shell, and a switch used for controlling the illumination module is arranged on the outer side of the shell;

the illumination module comprises a plurality of LED light-emitting chips and a fixing plate for fixing the LED light-emitting chips, the peak wavelength range of the LED light-emitting chips is 600-1000nm, the LED light-emitting chips can generate pulsed light to act on uterine muscle cells to form a phototherapy area to promote synthesis and release of nitric oxide and release of cyclic adenosine monophosphate, and the concentration of calcium ions in the uterine muscle cells is adjusted, so that relaxation of uterine smooth muscles is induced, blood flow is increased, and dysmenorrhea is relieved;

and the control module is electrically connected with the LED light-emitting chip and can carry out independent constant current driving and PWM dimming on the LED light-emitting chip.

2. The phototherapy device according to claim 1, wherein the PWM dimming amplitude is set in a range of 1-5V, the frequency is set in a range of 20 Hz-20 kHz, the duty ratio is set in a range of 0-100%, the control module outputs a PWM signal to the LED light emitting chip in an amplitude range of 1-5V, a PWM frequency range of 20 Hz-20 kHz, and a duty ratio range of 0-100%.

3. The phototherapy device according to claim 2, wherein the PWM signals outputted from the control module to the LED light emitting chips include an output current signal, an output voltage signal, an operating frequency signal and an operating time signal.

4. The phototherapy device for alleviating primary dysmenorrhea of claim 1, wherein a reflective membrane is disposed on one side of the fixing plate, which is close to the human body, for increasing the light utilization efficiency.

5. The phototherapy device as claimed in claim 1, wherein the housing is made of skin-friendly material, and the two ends of the housing are connected with straps by snap fasteners, and the housing can be fixed on the body by the straps.

6. The phototherapy device for alleviating primary dysmenorrhea of claim 1, wherein said switch is a push button, and the activation, deactivation, illumination time and gear size of said LED light emitting chip can be controlled by said push button.

7. The phototherapy device according to claim 1, wherein a voice module is further disposed in the housing, and the voice module is configured to send a voice prompt when the switch is operated.

8. A phototherapy device as claimed in claim 1, wherein the housing is an arc-shaped housing.

9. The phototherapy device for alleviating primary dysmenorrhea according to claim 1, wherein the light power of the LED light emitting chip is in the range of 1-30 mW/cm²。

10. A method of alleviating primary dysmenorrhea with a phototherapy device comprising the steps of:

s01 activating the phototherapy device for relief of primary dysmenorrhea of claim 1 5 days before a menstrual period;

s02, setting gears of the phototherapy device according to symptom conditions, and setting phototherapy time for 10-20 minutes;

s03 applying the phototherapy device to the skin surface between about two to four fingers wide below the navel eye;

s04 waiting sitting or lying down until the phototherapy device phototherapy is finished;

s05 repeating the steps S02-S04 to make the usage time of the day not less than 20 minutes.

Technical Field

The invention relates to the technical field of medical instruments, in particular to a phototherapy device for relieving primary dysmenorrhea.

Background

Primary dysmenorrhea (hereinafter, dysmenorrhea) refers to menstrual pain, which is usually concentrated in lower abdomen in spasm. Other symptoms include headache, weakness, dizziness, nausea, vomiting, diarrhea, lumbago and skelalgia, which are very common symptoms in young women. With the continuous and deep research on the pathogenesis and prevention and treatment of PD, the current pathogenesis of dysmenorrhea is clearer. Prostaglandins, vasopressin, oxytocin, sex hormones, endorphins, calcium ions and the like are considered to have close relationship with dysmenorrhea.

The first is Prostaglandins (PG), which are considered to be the fundamental mechanism for the development of dysmenorrhea. Prostaglandins (PGs) produced by the cyclooxygenase pathway are involved in regulating the contraction and relaxation of uterine muscle cells. The prostaglandins currently under investigation are PGE2 and PGF 2. Both of these PGs are present in the endometrium and are characterized by their content varying periodically. In non-pregnant uterus, PGE2 acts to inhibit spontaneous activity of uterine smooth muscle, while PGF2 promotes uterine smooth muscle contraction, reducing uterine blood flow, therefore, the current uterine scaling state is generally considered in combination with the ratio PGF2/PGE 2. If the ratio is too high, PGF2 receptors acting on the wall of the spiral arteriole will cause spastic contraction of uterine smooth muscle, stimulating pain receptors. Thus, by inhibiting the binding of PGF2 to its receptor, or by reducing the biosynthesis of PGs, dysmenorrhea relief may be achieved.

Vasopressin (AVP) also causes enhanced activity of the myometrium and uterine contractions by binding to the uterine V1 vasopressin receptor. In addition, AVP also promotes PG production and is sensitive to contraceptives.

Oxytocin (OT) can directly lean to uterine muscle cells, cause uterine contraction through intracellular biochemical pathways, simultaneously activate the circulation of phospho-femoral alcohol, and regulate the generation of local PGs, thereby aggravating dysmenorrhea. Notably, OT and PGF2 have synergistic effects, which promote release from each other. Therefore, dysmenorrhea can also be alleviated by inhibiting oxytocin synthesis.

Sex hormones, such as estradiol and progesterone, while not acting directly, can modulate PG biosynthesis. Specifically, the progestogen can promote the estradiol to be converted into inactive estrone, thereby reducing the generation of PGs, reducing the contraction and relaxation activity of uterine smooth muscle and achieving the effect of relieving dysmenorrheal. Beta-endorphins (beta-EP) are a class of neuropeptides with morphine-like activity, with endogenous analgesic action, present in the endometrium and subject to sex hormones. Progesterone can increase the secretion of beta-EP, but estradiol inhibits this effect. The reduction of β -EP levels at luteal phase is considered to be one of the causes of dysmenorrhea.

When dysmenorrhea occurred, the uterus was in ischemia-reperfusion injury state, and calcium (Ca2+) was allowed to enter into cells in large amount. This overloads intracellular calcium, and energy is depleted, causing damage to cell membranes, resulting in uterine muscle contractures leading to dysmenorrhea. Clinical studies have shown that dysmenorrhea can be treated by the use of calcium channel blockers (such as nicardipine). This also confirms that calcium ions are one of the causes.

The current major therapeutic approaches can be divided into drug therapy and non-drug therapy. The first category of pharmacotherapeutic agents include hormonal contraceptives, calcium channel blockers, and non-steroidal, all-anti-inflammatory drugs. Currently the most used non-steroidal anti-inflammatory drugs are available. The principle is that the central nervous system on the activity level is directly analgetic and pain relieving effect is achieved by interrupting the activity of cyclooxygenase and inhibiting the generation of pain-causing substances such as PG. However, nsaid therapy still has a failure rate of 20% to 25%, and some drugs may be contraindicated and may not be tolerated by women. In addition, the non-steroidal anti-inflammatory drug is a weak acid drug, which can cause damage to the gastric mucosa and severe cause gastric erosion, ulcer and gastrointestinal bleeding. Another class of non-drug therapies is primarily three, Transcutaneous Electrical Nerve Stimulation (TENS), high intensity aerobic exercise, and acupuncture and acupressure. TENS is an effective method for relieving dysmenorrhea, and primary dysmenorrhea can be relieved through three ways.

Photobiomodulatology (photobiomodulation) is a novel non-drug treatment modality, and clinical trials have shown that LED phototherapy can effectively reduce the VAS score of dysmenorrhea. The method utilizes the group pulse technology to inject light energy with specific intensity, specific frequency and various wave bands into the uterus of a human body, stimulate uterine muscle cells, promote the release of intracellular cyclic adenosine monophosphate (cAMP) and simultaneously promote the synthesis and release of intracellular Nitric Oxide (NO). As NO is increased and released from cells and tissues, NO penetrates the cells, promotes the expansion of blood vessels, and induces the relaxation of uterine smooth muscle through nitrogen energy neurotransmission, thereby increasing blood flow and exerting analgesic effect. In addition, the uterus muscle cells are also photostimulated, and the intracellular calcium ion concentration can be adjusted, so that the intracellular calcium ion overload is prevented.

In conclusion, the method not only effectively avoids the problem of personal drug tolerance of women, but also has no side effect, and is a good method for solving the primary dysmenorrhea. Based on this mechanism of action, the present invention provides a phototherapy device for reducing primary menstrual pain.

Disclosure of Invention

It is an object of the present invention to overcome the problems of the prior art and to provide a phototherapy device for alleviating primary dysmenorrhea.

In order to achieve the purpose, the invention adopts the following scheme:

a phototherapy device for alleviating primary dysmenorrhea, comprising:

the illumination device comprises a shell, wherein an illumination module and a control module electrically connected with the illumination module are arranged in the shell, and a switch for controlling the illumination module is arranged on the outer side of the shell;

the illumination module comprises a plurality of LED light-emitting chips and a fixing plate for fixing the LED light-emitting chips, wherein the peak wavelength range of the LED light-emitting chips is 600-1000nm, preferably 610nm, 630nm and 660 nm. The LED light-emitting chip can generate pulsed light to act on uterine muscle cells to form a phototherapy area to promote synthesis and release of nitric oxide and release of cyclic adenosine monophosphate, and the concentration of calcium ions in the uterine muscle cells is adjusted, so that relaxation of uterine smooth muscles is induced, blood flow is increased, and dysmenorrhea is relieved;

and the control module is electrically connected with the LED light-emitting chip and can carry out independent constant current driving and PWM dimming on the LED light-emitting chip.

Furthermore, the setting range of the PWM dimming amplitude is 1-5V, the setting range of the frequency is 20 Hz-20 kHz, the setting range of the duty ratio is 0-100%, the amplitude range of the PWM signal output by the control module to the LED light-emitting chip is 1-5V, the PWM frequency range is 20 Hz-20 kHz, and the duty ratio range is 0-100%.

Further, the PWM signal output by the control module to the LED light emitting chip includes an output current signal, an output voltage signal, a working frequency signal, and a working time signal.

Furthermore, a reflective membrane for improving the light energy utilization rate is arranged on one side of the fixing plate, which is attached to the human body.

Further, the casing comprises close skin material, and casing both ends buckle is connected with the bandage, and casing accessible bandage is fixed on the human body.

Furthermore, the switch is a push type key, and the starting, the closing, the illumination time and the gear size of the LED light-emitting chip can be controlled through the key.

Furthermore, still locate voice module in the casing, voice module can send pronunciation when operating switch and remind.

Further, the shell is an arc-shaped shell.

Furthermore, the luminous power range of the LED luminous chip is 1-30 mW/cm²。

A method of alleviating primary dysmenorrhea with a phototherapy device comprising the steps of:

s01 activating the phototherapy device for relief of primary dysmenorrhea of claim 1 5 days before a menstrual period;

s02, setting gears of the phototherapy device according to symptom conditions, and setting phototherapy time for 10-20 minutes;

s03 applying the phototherapy device on the skin surface between two fingers and four fingers under the navel;

s04 standing still for sitting or lying down until the phototherapy device finishes phototherapy;

s05 repeating S02-S04 to make the usage time of the day not less than 20 minutes.

Compared with the prior art, the invention has the following advantages: the LED light-emitting chip of the phototherapy device for relieving primary dysmenorrhea can generate pulsed light to act on uterine muscle cells to form a phototherapy area to promote synthesis and release of nitric oxide and release of cyclic adenosine monophosphate, and the concentration of calcium ions in the uterine muscle cells is adjusted, so that relaxation of uterine smooth muscles is induced, blood flow is increased, and the pain intensity of female primary dysmenorrhea can be effectively relieved. Meanwhile, the phototherapy device for relieving primary dysmenorrhea has no wound and discomfort on human epidermal skin, and has no side effect and dependence.

Drawings

The present application will be described in further detail with reference to the following drawings and detailed description.

Fig. 1 is a schematic structural diagram of the whole phototherapy device for alleviating primary dysmenorrhea in accordance with the present invention

Fig. 2 is a schematic structural diagram of an illumination module of a phototherapy device for alleviating primary dysmenorrhea in accordance with the present invention.

Detailed Description

The following detailed description of embodiments of the present invention is provided in connection with the accompanying drawings and examples. The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.

As shown in fig. 1, a phototherapy device for alleviating primary dysmenorrhea comprises:

the lighting device comprises a shell 3, wherein an illumination module 1 and a control module 2 electrically connected with the illumination module 1 are arranged in the shell 3, and a switch for controlling the illumination module 1 is arranged on the outer side of the shell 3;

illumination module 1, illumination module 1 include a plurality of LED luminescence chip 4 and be used for fixed LED luminescence chip 4 fixed plate 7, and LED luminescence chip 4 passes through fixed plate 7 to be fixed in casing 3, and the quantity of LED luminescence chip 4 is no less than 5, and preferred 36 array distributions are on fixed plate 7 in this embodiment. The peak wavelength range of the LED light-emitting chip 4 is 600-1000nm, and preferably 610nm, 630nm and 660 nm. The LED light-emitting chip 4 can generate pulsed light to act on uterine muscle cells to form a phototherapy area to promote synthesis and release of nitric oxide and release of cyclic adenosine monophosphate, and the concentration of calcium ions in the uterine muscle cells is adjusted, so that relaxation of uterine smooth muscles is induced, blood flow is increased, and dysmenorrhea is relieved;

and the control module 2 is electrically connected with the LED light-emitting chip 4, and the control module 2 can carry out independent constant current driving and PWM dimming on the LED light-emitting chip 4.

Preferably, the setting range of the PWM dimming amplitude is 1-5V, the setting range of the frequency is 20 Hz-20 kHz, the setting range of the duty ratio is 0-100%, the amplitude range of the PWM signal output by the control module 2 to the LED light-emitting chip 4 is 1-5V, the PWM frequency range is 20 Hz-20 kHz, and the duty ratio range is 0-100%.

Preferably, the PWM signal output by the control module 2 to the LED light emitting chip 4 includes an output current signal, an output voltage signal, an operating frequency signal and an operating time signal.

Preferably, a reflective membrane 6 for improving the light energy utilization rate is arranged on one side of the fixing plate 7, which is attached to the human body.

Preferably, the shell 3 is made of skin-friendly material, two ends 11 of the shell 3 are connected with a binding belt 10 through a buckle, and the shell 3 can be fixed on a human body through the binding belt 10.

Preferably, the switch is a press-type key 8, and the key 8 can control the on/off, illumination time and gear size of the LED light-emitting chip 4. The key 8 is connected with the control module 2. The control module 2 is responsible for receiving and processing signals from the keys 8. The gear of the device is set to 3 gears and can be adjusted through the key 8. When the key 8 is pressed for a long time, the device is started or closed. When the key 8 is double-clicked, the gear is adjusted. Whenever the key 8 is pressed, there is a voice prompt. The light intensity is strongest in the No. 3 position, the second in the No. 2 position and the weakest in the No. 1 position.

Preferably, still locate voice module in the casing 3, voice module can send out the pronunciation and remind when operating the switch.

Preferably, the housing 3 is an arc-shaped housing 3. The utility model is attached to the part from two fingers to four fingers under the navel of human body, thus improving the use experience.

Preferably, the light power range of the LED light-emitting chip 4 is 1-30 mW/cm²。

A method of alleviating primary dysmenorrhea with a phototherapy device comprising the steps of:

s01 activating the phototherapy device for relief of primary dysmenorrhea of claim 1 5 days before a menstrual period;

s02, setting gears of the phototherapy device according to symptom conditions, and setting phototherapy time for 10-20 minutes;

s03 applying the phototherapy device on the skin surface between two fingers and four fingers under the navel;

s04 standing still for sitting or lying down until the phototherapy device finishes phototherapy;

s05 repeating S02-S04 to make the usage time of the day not less than 20 minutes.

Compared with the prior art, the invention has the following advantages: the LED light-emitting chip 4 of the phototherapy device for relieving primary dysmenorrhea can generate pulsed light to act on uterine muscle cells to form a phototherapy area to promote synthesis and release of nitric oxide and release of cyclic adenosine monophosphate, and the concentration of calcium ions in the uterine muscle cells is adjusted, so that relaxation of uterine smooth muscles is induced, blood flow is increased, and the pain intensity of female primary dysmenorrhea can be effectively relieved. Meanwhile, the phototherapy device for relieving primary dysmenorrhea has no wound and discomfort on human epidermal skin, and has no side effect and dependence.

The foregoing is only a preferred embodiment of the present application, and it should be noted that, for those skilled in the art, several modifications and substitutions can be made without departing from the technical principle of the present application, and these modifications and substitutions should also be regarded as the protection scope of the present application.